0001209191-20-037335.txt : 20200617 0001209191-20-037335.hdr.sgml : 20200617 20200617171247 ACCESSION NUMBER: 0001209191-20-037335 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200615 FILED AS OF DATE: 20200617 DATE AS OF CHANGE: 20200617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fischer Laurent CENTRAL INDEX KEY: 0001379344 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36579 FILM NUMBER: 20970489 MAIL ADDRESS: STREET 1: C/O PANACOS PHARMACEUTICALS, INC. STREET 2: 134 COOLIDGE AVENUE CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc. CENTRAL INDEX KEY: 0001501756 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205258327 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-272-6269 MAIL ADDRESS: STREET 1: 800 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc. DATE OF NAME CHANGE: 20100921 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-15 0 0001501756 Adverum Biotechnologies, Inc. ADVM 0001379344 Fischer Laurent C/O ADVERUM BIOTECHNOLOGIES, INC. 800 SAGINAW DRIVE REDWOOD CITY CA 94063 1 1 0 0 CEO and Director Stock Option (Right to Buy) 23.70 2020-06-15 4 A 0 1200000 0.00 A 2030-06-14 Common Stock 1200000 1200000 D Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of June 15, 2020 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to 24 months of accelerated vesting and a 24-month post-termination exercise period in certain events, and subject to the Reporting Person's continued service with the Issuer on each such vesting date. Laurent D. Fischer, by /s/ Peter Soparkar, Attorney-in-Fact 2020-06-17